PMID- 29414548
OWN - NLM
STAT- MEDLINE
DCOM- 20190301
LR  - 20211204
IS  - 1525-5069 (Electronic)
IS  - 1525-5050 (Linking)
VI  - 80
DP  - 2018 Mar
TI  - Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy 
      in patients with epilepsy: A retrospective single center study.
PG  - 173-176
LID - S1525-5050(17)30898-3 [pii]
LID - 10.1016/j.yebeh.2018.01.001 [doi]
AB  - Perampanel (PER) is a third generation antiepileptic drug (AED), recently 
      approved as add-on therapy in both focal and generalized seizures. Levetiracetam 
      (LEV) is a second generation AED, widely used in patients with epilepsy because 
      of its favorable safety and efficacy profiles. Perampanel and LEV treatments have 
      been associated with the occurrence of similar adverse events (AEs) (sleepiness, 
      irritability, depression, anxiety, aggressiveness). The aim of the present 
      retrospective single center study was to verify the efficacy and tolerability of 
      PER and LEV used as first add-on therapy in patients with epilepsy affected by 
      secondarily generalized seizures. We collected data from 15 patients treated with 
      PER and 26 patients treated with LEV and followed at our site with follow-up 
      visits at 3, 6, and 12months. This retrospective study documented the comparable 
      efficacy of PER and LEV as first add-on treatments in patients affected by 
      uncontrolled secondarily generalized seizures. However, more patients withdrawn 
      LEV because of AEs compared with PER at the 3- and 12-month follow-up visits. The 
      better tolerability of PER observed in this study could be related to the low 
      therapeutic dose of PER prescribed when it is used as first adjunctive treatment 
      for better controlling secondarily generalized seizures.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Liguori, Claudio
AU  - Liguori C
AD  - Epilepsy Centre, Neurophysiopathology Unit, Department of Systems Medicine, 
      University of Rome "Tor Vergata", Rome, Italy. Electronic address: 
      liguori@med.uniroma2.it.
FAU - Izzi, Francesca
AU  - Izzi F
AD  - Epilepsy Centre, Neurophysiopathology Unit, Department of Systems Medicine, 
      University of Rome "Tor Vergata", Rome, Italy.
FAU - Manfredi, Natalia
AU  - Manfredi N
AD  - Epilepsy Centre, Neurophysiopathology Unit, Department of Systems Medicine, 
      University of Rome "Tor Vergata", Rome, Italy.
FAU - D'Elia, Alessio
AU  - D'Elia A
AD  - Epilepsy Centre, Neurophysiopathology Unit, Department of Systems Medicine, 
      University of Rome "Tor Vergata", Rome, Italy.
FAU - Mari, Luisa
AU  - Mari L
AD  - Epilepsy Centre, Neurophysiopathology Unit, Department of Systems Medicine, 
      University of Rome "Tor Vergata", Rome, Italy.
FAU - Mercuri, Nicola Biagio
AU  - Mercuri NB
AD  - Epilepsy Centre, Neurophysiopathology Unit, Department of Systems Medicine, 
      University of Rome "Tor Vergata", Rome, Italy; IRCCS Fondazione Santa Lucia, 
      Rome, Italy.
FAU - Fabio, Placidi
AU  - Fabio P
AD  - Epilepsy Centre, Neurophysiopathology Unit, Department of Systems Medicine, 
      University of Rome "Tor Vergata", Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20180203
PL  - United States
TA  - Epilepsy Behav
JT  - Epilepsy & behavior : E&B
JID - 100892858
RN  - 0 (Anticonvulsants)
RN  - 0 (Nitriles)
RN  - 0 (Pyridones)
RN  - 44YRR34555 (Levetiracetam)
RN  - H821664NPK (perampanel)
SB  - IM
MH  - Adult
MH  - Aggression
MH  - Anticonvulsants/administration & dosage/adverse effects/*therapeutic use
MH  - Anxiety
MH  - Depression
MH  - Dizziness/chemically induced
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Epilepsy/*drug therapy/epidemiology
MH  - Female
MH  - Humans
MH  - Irritable Mood/drug effects
MH  - Levetiracetam/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Nitriles
MH  - Pyridones/administration & dosage/adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Seizures/*drug therapy
MH  - Treatment Outcome
MH  - Wakefulness
OTO - NOTNLM
OT  - Adverse events
OT  - Efficacy
OT  - Levetiracetam
OT  - Perampanel
OT  - Tolerability
EDAT- 2018/02/08 06:00
MHDA- 2019/03/02 06:00
CRDT- 2018/02/08 06:00
PHST- 2017/10/27 00:00 [received]
PHST- 2018/01/04 00:00 [revised]
PHST- 2018/01/04 00:00 [accepted]
PHST- 2018/02/08 06:00 [pubmed]
PHST- 2019/03/02 06:00 [medline]
PHST- 2018/02/08 06:00 [entrez]
AID - S1525-5050(17)30898-3 [pii]
AID - 10.1016/j.yebeh.2018.01.001 [doi]
PST - ppublish
SO  - Epilepsy Behav. 2018 Mar;80:173-176. doi: 10.1016/j.yebeh.2018.01.001. Epub 2018 
      Feb 3.